Hematopoietic SCT (HSCT) after non-myeloablative conditioning is associated with reduced TRM, and increased risk of graft rejection. Although preclinical data have shown the importance of post transplant immunosuppression in achieving engraftment, little is known about the role of CSA in the clinical setting of non-myeloablative transplantation. In a retrospective analysis of patients treated with allogeneic HSCT after fludarabine and 2 Gy TBI, 15 of 77 evaluable patients (20%) experienced primary (n ¼ 2) or secondary graft rejection at a median of 66 days post transplant. Mean day 1-28 CSA trough levels were inversely associated with day 28 chimerism (median 99, 85 and 70% for mean CSA o300, 300-600 and 4600 ng/mL, respectively; P ¼ 0.003). A similar association was observed for the cumulative incidence of graft rejection, which occurred in 8% (o300 ng/mL), 26% (300-600 ng/mL) and 50% (4600 ng/mL, P ¼ 0.005) of patients. The detrimental effect of high CSA levels on engraftment was confirmed in multivariable models and was found to operate comparably in sibling and unrelated donor transplants. Impairment of donor T-cell function by high serum levels of CSA might account for this finding, which should be verified in a larger patient group to better understand the role of CSA in non-myeloablative transplantation.
Introduction
The past decade has seen an increasing use of nonmyeloablative conditioning regimens for allogeneic hematopoietic SCT. 1, 2 Although this treatment modality is associated with reduced TRM compared with myeloablative protocols, risk of graft rejection is increased owing to higher numbers of host effector cells remaining after conditioning. [3] [4] [5] [6] [7] Graft rejection is usually followed by autologous hematopoietic recovery and is therefore rarely fatal. However, it renders the transplant futile and often leads to a second transplant with more intensive conditioning, which in turn increases the risk of TRM.
Some factors associated with graft rejection have been identified, such as graft manipulation, 8, 9 HLA disparity, 10 underlying disease 5, 11 and graft source. 11 In the development of non-myeloablative regimens in animal models, intensive post transplant immunosuppression had an important role in achieving stable engraftment, leading to the general concept of intensive immunosuppression in the non-myeloablative setting. 12 Among other findings, a beneficial effect of CSA could be shown. 13, 14 However, little is known about the influence of CSA levels on graft rejection in human beings in the corresponding clinical setting. Therefore, we performed a retrospective analysis on patients treated with a nonmyeloablative transplant at our institution and attempted to identify the role of CSA in graft rejection.
Patients and methods

Study design and definitions
We performed a retrospective cohort study including all consecutive patients treated at our institution with the nonmyeloablative regimen developed by the Seattle/Leipzig groups. The conditioning regimen consisted of fludarabine (3 Â 30 mg/m 2 , days -4 to -2) and 2 Gy TBI (day 0) in all patients.
Graft rejection was defined as either o5% donor cells on day 28 (primary graft failure), o5% donor cells at day 29 or later after transient engraftment of donor-origin hematopoiesis, or re-transplantation for pancytopenia with concurrent loss of chimerism (both classified as secondary graft rejection). Disease stage was classified as early (chronic myeloid leukemia in first chronic phase; acute leukemia/myelodysplastic syndrome/multiple myeloma/ lymphoma in first CR; all non-malignant indications) or advanced (all other stages). Acute GvHD (aGvHD) was graded according to the Glucksberg criteria. 15 HLA typing was performed at a high-resolution (four-digit) level for all patients with an unrelated donor and at a low-resolution (two-digit) level for those with a related donor.
Patient characteristics
Between October 1999 and December 2008, 84 patients were treated with the described non-myeloablative allogeneic transplant at our institution either because they were not eligible for myeloablative conditioning or owing to disease-specific protocols. Seven patients were not evaluable for engraftment and therefore excluded from the analysis for the following reasons: six had graft failure associated with early relapse precluding a definitive analysis of engraftment stability, and in one patient data on chimerism were incomplete. Table 1 shows patient and transplant characteristics of the remaining 77 patients. In all seven patients who had failed a previous allogeneic transplant, there was no residual donor chimerism detectable. The same donor was used for the second transplant in all seven patients.
Management of patients post transplant
GvHD prophylaxis consisted of CSA (6.25 mg/kg p.o. twice daily, started on day À3) and mycophenolate mofetil (MMF) (15 mg/kg p.o. twice daily, started on day 0). Patients incapable of enteral nutrition received CSA (1.5 mg/kg) and MMF (15 mg/kg) i.v. twice daily. CSA trough levels were measured at least once weekly and additionally after dose adjustments in all patients, with a target level of 200 ng/mL, although adjustments for levels above target were performed only in the case of toxicity (for example, renal toxicity or hypertension). MMF levels were not measured systematically. Declining donor chimerism or early relapse was treated by reduction of immunosuppression no earlier than day 28 post transplant, followed by donor lymphocyte infusions, if patients were free from GvHD. In the absence of GvHD, CSA was tapered and discontinued by day 180. MMF was given until day 28 for patients with related donors, and was tapered and stopped by day 56 for those with unrelated donors.
Chimerism analysis in whole blood was carried out at days 28, 90, 180, 365 and yearly thereafter or when deemed clinically relevant. Chimerism was measured quantitatively using a STR analysis method (AmpFlSTR Profiler, Applied Biosystems, Foster City, CA, USA). Trough CSA serum levels were analyzed using a fluorescence polarization immunoassay (Abbott Laboratories, Abbott Park, IL, USA) until 2005 and by a cloned enzyme donor immunoassay (CEDIA, Thermo Fisher Scientific, Waltham, MA, USA) thereafter. Mean CSA serum levels of days 1-28 were calculated by dividing the area under the curve of CSA levels in that period by 28.
Statistical analysis
Incidences of graft rejection and aGvHD were calculated treating death from any cause as a competing event. Incidence of disease relapse was calculated treating death in remission as a competing event. Cumulative incidences were compared using Gray's test. Multivariable analyses were conducted using Cox models. Covariates analyzed in Cox models were donor type (unrelated vs sibling), HLA match, graft source, previous transplant (allogeneic vs autologous vs none), disease (chronic myeloid leukemia/ myeloproliferative neoplasm vs other), disease stage, graft nucleated cell count, graft CD34 cell count, CSA day 1-28 mean through levels, donor sex, recipient sex, patient age, year of transplant, EBMT risk score and Karnofsky index. Covariates were included in a stepwise forward selection manner.
Patient and transplant characteristics were compared using Pearson's w 2 test for categorical and Mann-Whitney U-test for continuous variables. The relationship between CSA serum levels and year of transplant was analyzed by linear regression, and that of CSA and creatinine serum Table 1 Patient characteristics 
Results
Engraftment
Of the 77 patients evaluated, 15 (20%; 95% confidence interval (CI) 13-31%) rejected their graft at a median of 66 days (29-180) post transplant ( Figure 1 ). Two patients experienced primary graft failure, while 10 others had varying levels of donor chimerism before graft loss. Three patients were re-transplanted for severe pancytopenia/BM hypoplasia with imminent loss of donor chimerism. Of the patients with graft rejection, nine had a related donor and six had an unrelated donor. Chronic myeloid leukemia/ myeloproliferative neoplasm as underlying disease was overrepresented in the group who rejected, whereas all patients with multiple myeloma achieved stable engraftment; however, these differences only reached borderline statistical significance. All other factors were distributed evenly (Table 1) . Figure 2a ). Furthermore, there was a significant association between mean day 1-28 trough CSA level and year of transplant with higher levels found in earlier years (Po0.001; Figure 2b ). However, both factors accounted for only a small part of the variation observed (r 2 ¼ 0.06 and 0.16, respectively).
CSA levels
Influence of CSA levels on risk of graft rejection Figure 3a depicts levels of day 28 chimerism in patients according to mean trough CSA serum level achieved in the first 4 weeks post transplant: chimerism was highest in patients with mean CSA levels of o300 ng/mL during the first 4 weeks post transplant (N ¼ 40, median chimerism ¼ 99%), intermediate in the 300-600 ng/mL group (N ¼ 27, median chimerism 85%) and lowest in the group of patients with mean CSA levels exceeding 600 ng/mL (N ¼ 10, median chimerism 70%). A higher day 28 chimerism strongly protected from future graft rejection (hazard ratio (HR) for graft loss for each increasing percent of chimerism ¼ 0.95, 95% CI 0.93-0.97, Po0.001).
Resulting from these two associations, we found a significantly increased risk for graft loss in patients with high exposure to CSA in the first 4 weeks post transplant. Figure 3b compares CSA levels in patients with or without eventual graft rejection on days 1, 8, 15, 22 and 29 after transplantation. Throughout the first 4 weeks, median CSA levels were higher in patients who would later reject their graft (all comparisons Po0.01). Eventually, 8% (95% CI 2-18%) of patients with a mean trough CSA concentration o300 ng/mL lost their graft. This rate increased to 26% (95% CI 11-44%) in the 300-600 ng/mL group and to 50% (95% CI 16-77%) in the 4600 ng/mL group (Figure 3c ;
In a multivariate analysis of factors effecting the risk graft rejection, CSA level remained statistically significant ( Table 2 ). HR for graft loss per increasing ng/mL of mean CSA level was 1.005 (95% CI 1.002-1.008), corresponding to a risk of rejection growing by 0.5% for each increase of CSA level of 1 ng/mL during the first 4 weeks after transplantation. When CSA levels were categorized and the o300 ng/mL group taken as the reference range, hazard rates for transplant rejection were 3.47 (95% CI 0.79-15.3) in the 300-600 ng/mL group and 14.9 (95% CI 2.28-96.8) in the 4600 ng/mL group. The effect of CSA levels on graft rejection was comparable in patients transplanted from a sibling donor (HR per increasing ng/mL CSA 1.006, 95% CI 1.002-1.009) or from an unrelated donor (HR 1.005, 95% CI 0.996-1.014). Donor type also significantly influenced the risk of graft failure in the multivariate analysis (HR unrelated donor vs sibling donor 6.81, 95% CI 1.56-29.8, P ¼ 0.01). Pre-transplant variables without statistically significant impact on engraftment were donor and recipient sex, patient age, graft source, year of transplant, CD34 count, disease stage, EBMT risk score and Karnofsky index.
GvHD and relapse incidence
In the entire patient group, the cumulative incidence of aGvHD grade II-IV was 35% (95% CI 25-46%). Considering only patients with stable engraftment, there was no significant difference between patients grouped according to CSA levels (4300, 300-600 and 4600 ng/mL) with aGvHD grade II-IV rates of 54, 37 and 40%, Figure 3 Peripheral blood donor chimerism levels in patients grouped according to mean day 1-28 trough CSA levels (o300, 300-600 and 4600 ng/mL). Median levels of donor chimerism on day 28 were 99, 85 and 70% (P ¼ 0.003), respectively (a). CSA serum levels in patients with and without stable engraftment (light gray and dark gray bars, respectively) on days 1, 8, 15, 22 and 29 after non-myeloablative hematopoietic SCT. Horizontal lines represent medians, boxes interquartile ranges and whiskers 2.5 and 97.5 percentiles. P-value for all comparisons o0.01 (b). Cumulative incidence of graft rejection in patients grouped accordingly. Graft rejection occurred in 8, 26 and 50% of patients, respectively (P ¼ 0.005; c). respectively. The incidence of relapse was also not influenced by the CSA level among patients with stable engraftment (data not shown).
P=0.005
Discussion
We show here a retrospective analysis of the influence of CSA levels on graft rejection following non-myeloablative conditioning for allogeneic transplantation. In our cohort of 77 evaluable patients who received fludarabine and 2 Gy TBI as conditioning, 15 patients (20%) experienced graft rejection. In the attempt to elucidate the role of CSA levels, we began by evaluating measured trough levels in the first month post transplant. We observed a fairly constant median CSA level, but a large interquartile range, which in turn prompted us to analyze factors influencing CSA levels. This showed a significant negative association of creatinine and CSA levels as an indicator that CSA dose was subsequently reduced in patients who experienced renal toxicity. Furthermore, we observed a correlation of transplant year and CSA levels (higher levels in earlier years). The reason for lower CSA serum levels in later years remains unclear.
We observed a marked association between CSA level and day 28 donor chimerism, and more importantly the rate of graft rejection. This remained significant in a multivariate analysis, in which donor type was the only other statistically significant factor identified. The increased risk of graft rejection with unrelated donors has been observed previously. 16, 17 However, to our knowledge, there are no reports on the association of increased CSA levels and the risk of graft rejection.
Before clinical use, the non-myeloablative conditioning regimen used in our patients was extensively studied in a large animal model, and efforts are ongoing to optimize pre-and post transplant treatment schedules. 12, 18 These studies have predominantly shown that reducing the intensity of the conditioning regimen or post transplant immunosuppression increases the risk of graft rejection. [12] [13] [14] 19, 20 This was confirmed in the clinical setting. Patients conditioned with 2 Gy TBI alone had a higher rate of graft rejection compared with those receiving fludarabine additionally, 21 whereas increasing the dose of MMF post transplant likewise increased the proportion of patients with stable engraftment. 22 Along this line, in the setting of a slightly more intensive conditioning regimen and using a T-cell-depleted graft, a correlation was shown between recipient pre-transplant T-cell counts and decreased donor chimerism. 23 However, there have also been observations of the potentially detrimental effect of high CSA doses in the myeloablative setting, as mentioned above. In two randomized studies, higher doses of CSA led to a significantly increased risk of relapse, which translated into a decreased disease-free survival. 24, 25 This indicates that, despite the essential nature of post transplant immunosuppression, 'too much' immunosuppression inhibits the GVL effect, one of the main principles of the curative potential of allogeneic transplant. This is also reflected by the observation that remissions can be induced by discontinuation of immunosuppression. [26] [27] [28] Both GVL effects and engraftment stability rely on donor T-lymphocytes co-transplanted with hematopoietic stem cells. 29 Excessive CSA levels might functionally compromise donor T-lymphocytes and thereby hamper engraftment, an assumption supported by the observation that patients with mixed chimerism can successfully be converted to full chimeras by the withdrawal of immunosuppression. 30, 31 Another aspect that needs to be considered is evidence suggesting an interaction between CSA and MMF, leading to decreased levels of MMF. 32, 33 In turn, as mentioned above, increased MMF exposure has been shown to be protective against graft rejection. This leads to the speculation that the increased rate of graft rejection we observed with elevated CSA levels might have been mediated at least in part by insufficient MMF levels in patients with supratherapeutic CSA levels. Unfortunately, we did not systematically measure MMF levels in our patients precluding any analysis in this regard.
In conclusion, our report shows a significant association of elevated CSA levels and the risk of graft rejection following non-myeloablative conditioning, suggesting that excessive immunosuppression inhibits engraftment. Despite several limitations of this study including the retrospective setting as well as missing data on T-cell subset chimerism, T-cell content of the graft and pre-transplant T-cell counts, our data challenge the current concept of a need for particularly intensive immunosuppression after non-myeloablative hematopoietic SCT, and we believe that our findings should be verified in a larger group of patients to better define the role of CSA in this setting.
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